EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan

Keiko Asakawa, Miina Waratani, Olivia Massey, Tim Holbrook, Makoto Kondo, Atsushi Saito, Hiroyuki Nishiyama

International Journal of Urology · 2024

DOI: 10.1111/iju.15450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2024. Verfasst von Keiko Asakawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Transitional Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seagen, Astellas Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Evaluate real‐world epidemiologic trends and treatment patterns in newly diagnosed patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in Japan.

Methods

This retrospective analysis included adults with newly diagnosed la/mUC in Japan (January 2015–December 2019) from a nationwide‐linked electronic medical record Diagnostic Procedure Combination claims dataset. Outcomes included epidemiologic trends (incidence and prevalence), baseline demographics, clinical characteristics, and treatment patterns in newly diagnosed patients with la/mUC before (2015–2017) and after (2018–2019) approval of pembrolizumab in Japan.

Results

Of 975 patients included, 76.4% were men; 71.6% were aged 70 years or older. Most cases (70.5%) were of the bladder. Between 2015 and 2019, the annual age‐adjusted incidence increased from 6.8 to 12.4 per 100 000; the annual age‐adjusted period prevalence increased from 13.0 to 25.2 per 100 000; and 307 (31.5%) and 668 (68.5%) patients were diagnosed from 2015 to 2017 and 2018 to 2019, respectively. Overall, 731 (75%) patients received systemic anticancer therapy; all received 1 line and 50.2% received 2 lines of therapy; 78.3% of patients received gemcitabine plus platinum‐based therapy and 2.2% received pembrolizumab as first‐line treatment. First‐line treatment rates increased from 69.4% to 77.5% after pembrolizumab approval. Of 367 patients who received second‐line treatment, 22.3% received gemcitabine plus platinum‐based therapy; 14.7% received pembrolizumab.

Conclusions

In the Japanese regions considered, incidence and prevalence of newly diagnosed la/mUC increased over time and first‐line treatment with pembrolizumab increased after approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Transitional CellHumansMaleJapanRetrospective StudiesFemaleAgedMiddle AgedIncidenceAged, 80 and overUrinary Bladder NeoplasmsPrevalenceAdultUrologic NeoplasmsAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Japanepidemiologylocally advanced/ metastatic urothelial carcinomareal‐worldretrospective analysistreatment patterns

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Global Medical Affairs Japan, Astellas Pharma, Inc., Tokyo, Japan.
  • Secondary Data Evidence Generation, Adelphi Real World, Bollington, UK.
  • Department of Urology, Tsukuba University, Tsukuba, Japan.

Förderung

  • Seagen
  • Astellas Pharma

Zitieren

APA

Asakawa, K., Waratani, M., Massey, O., Holbrook, T., Kondo, M., Saito, A., & Nishiyama, H. (2024). Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan. International Journal of Urology. https://doi.org/10.1111/iju.15450

Vancouver

Asakawa K, Waratani M, Massey O, Holbrook T, Kondo M, Saito A, et al. Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan. International Journal of Urology. 2024. doi:10.1111/iju.15450

BibTeX
@article{Asakawa2024,
  author = {Asakawa, Keiko and Waratani, Miina and Massey, Olivia and Holbrook, Tim and Kondo, Makoto and Saito, Atsushi and Nishiyama, Hiroyuki},
  title = {Real‐world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan},
  journal = {International Journal of Urology},
  year = {2024},
  doi = {10.1111/iju.15450}
}
Kostenlos starten →